Evidence map›Paper›PMID 28173833›Full record

ArticleJournal of experimental & clinical cancer research : CR2017

Human breast adipose tissue: characterization of factors that change during tumor progression in human breast cancer.

Sabrina Johanna Fletcher, Paula Alejandra Sacca, Mercedes Pistone-Creydt, Federico Andrés Coló, María Florencia Serra, Flavia Eliana Santino, Corina Verónica Sasso, Constanza Matilde Lopez-Fontana, Rubén Walter Carón, Juan Carlos Calvo and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Leptin signaling in breast cancer and its crosstalk with peroxisome proliferator-activated receptors α and γ.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Targeting adipocyte-immune cell crosstalk to control breast cancer progression.Journal of cancer research and clinical oncology · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Sabrina Johanna FletcherLaboratory of Proteoglycans Chemistry and Extracellular Matrix, Institute of Biology and Experimental Medicine (IByME), National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Paula Alejandra SaccaLaboratory of Proteoglycans Chemistry and Extracellular Matrix, Institute of Biology and Experimental Medicine (IByME), National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Mercedes Pistone-CreydtGynecological Surgery and Breast Pathology, Oncology Institute "Alexander Fleming", Buenos Aires, Argentina.
Federico Andrés ColóGynecological Surgery and Breast Pathology, Oncology Institute "Alexander Fleming", Buenos Aires, Argentina.
María Florencia SerraLaboratory of Hormones and Cancer Biology, Institute of Medicine and Experimental Biology of Cuyo (IMBECU), National Scientific and Technical Research Council (CONICET), Mendoza, Argentina.
Flavia Eliana SantinoLaboratory of Hormones and Cancer Biology, Institute of Medicine and Experimental Biology of Cuyo (IMBECU), National Scientific and Technical Research Council (CONICET), Mendoza, Argentina.
Corina Verónica SassoLaboratory of Hormones and Cancer Biology, Institute of Medicine and Experimental Biology of Cuyo (IMBECU), National Scientific and Technical Research Council (CONICET), Mendoza, Argentina.
Constanza Matilde Lopez-FontanaLaboratory of Hormones and Cancer Biology, Institute of Medicine and Experimental Biology of Cuyo (IMBECU), National Scientific and Technical Research Council (CONICET), Mendoza, Argentina.
Rubén Walter CarónLaboratory of Hormones and Cancer Biology, Institute of Medicine and Experimental Biology of Cuyo (IMBECU), National Scientific and Technical Research Council (CONICET), Mendoza, Argentina.
Juan Carlos CalvoLaboratory of Proteoglycans Chemistry and Extracellular Matrix, Institute of Biology and Experimental Medicine (IByME), National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
Virginia Pistone-CreydtLaboratory of Proteoglycans Chemistry and Extracellular Matrix, Institute of Biology and Experimental Medicine (IByME), National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina. vpistone@mendoza-conicet.gob.ar.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARExperimental Medicine and Biology Institute · ARInstituto Alexander Fleming · ARInstituto de Medicina y Biología Experimental de Cuyo · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdipose microenvironment is involved in signaling pathways that influence breast cancer. We aim to characterize factors that are modified: 1) in tumor and non tumor human breast epithelial cell lines when incubated with conditioned media (CMs) from human breast cancer adipose tissue explants (hATT) or normal breast adipose tissue explants (hATN); 2) in hATN-CMs vs hATT-CMs; 3) in the tumor associated adipocytes vs. non tumor associated adipocytes.

methodsWe used hATN or hATT- CMs on tumor and non-tumor breast cancer cell lines. We evaluated changes in versican, CD44, ADAMTS1 and Adipo R1 expression on cell lines or in the different CMs. In addition we evaluated changes in the morphology and expression of these factors in slices of the different adipose tissues. The statistical significance between different experimental conditions was evaluated by one-way ANOVA. Tukey's post-hoc tests were performed within each individual treatment.

resultshATT-CMs increase versican, CD44, ADAMTS1 and Adipo R1 expression in breast cancer epithelial cells. Furthermore, hATT-CMs present higher levels of versican expression compared to hATN-CMs. In addition, we observed a loss of effect in cellular migration when we pre-incubated hATT-CMs with chondroitinase ABC, which cleaves GAGs chains bound to the versican core protein, thus losing the ability to bind to CD44. Adipocytes associated with the invasive front are reduced in size compared to adipocytes that are farther away. Also, hATT adipocytes express significantly higher amounts of versican, CD44 and Adipo R1, and significantly lower amounts of adiponectin and perilipin, unlike hATN adipocytes.

conclusionsWe conclude that hATT secrete a different set of proteins compared to hATN. Furthermore, versican, a proteoglycan that is overexpressed in hATT-CMs compared to hATN-CMs, might be involved in the tumorogenic behavior observed in both cell lines employed. In addition, we may conclude that adipocytes from the tumor microenvironment show a less differentiated state than adipocytes from normal microenvironment. This would indicate a loss of normal functions in mature adipocytes (such as energy storage), in support of others that might favor tumor growth.

Indexed as

ADAMTS1 ProteinAdipose TissueBiomarkers, TumorBreastBreast NeoplasmsCell LineCell ProliferationCellular MicroenvironmentCulture Media, ConditionedDisease ProgressionEpithelial CellsFemaleGene Expression Regulation, NeoplasticHumansHyaluronan ReceptorsMCF-7 CellsADAMTS1 ProteinADAMTS1 protein, humanADIPOR1 protein, humanBiomarkers, TumorCD44 protein, humanCulture Media, ConditionedHyaluronan ReceptorsReceptors, AdiponectinVCAN protein, humanVersicansBreast cancerBreast epithelial cellsEpithelial-stromal interactionsHuman breast adipose tissue

Identifiers

PMID28173833
PMCPMC5297209
OpenAlexW2586986838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.